GALECTIN THERAPEUTICS INC cotiza a 3.87 USD y tiene una capitalización bursátil de $390M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.08 | $-0.08 | $-0.13 | $-0.12 |
| Estimado | $-0.06 | $-0.10 | $-0.11 | $-0.16 |
| Sorpresa | -33.3% | +20.0% | -18.2% | +25.0% |
| Métrica | GALT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -157.9% | -32.0% | -125.9% |
| Current Ratio | 2.42 | 2.84 | -0.42 |
| Debt / Equity | — | 0.28 | — |